The Fly | ABEO

Approved Gene Therapy Product (Vyjuvek): Abeona Therapeutics has successfully developed and gained FDA approval for Vyjuvek, the first and only topical gene therapy for dystrophic epidermolysis bullosa (DEB), providing a significant first-mover advantage and revenue stream.

Specialized Gene Therapy Expertise: The company possesses deep knowledge and proprietary technology in developing AAV (Adeno-Associated Virus) vector-based gene therapies for rare genetic diseases, forming a robust platform for pipeline expansion.

Orphan Drug & Regulatory Incentives: Their focus on rare diseases like DEB and Sanfilippo syndrome allows them to leverage Orphan Drug Designations, Fast Track, and Breakthrough Therapy designations, accelerating development and granting extended market exclusivity.

Clinical Trial & Regulatory Success: Failure to achieve positive clinical trial results or obtain regulatory approvals for its product candidates could significantly impair Abeona's ability to commercialize therapies and generate revenue.

Funding & Capital Availability: Abeona will require substantial additional capital to fund its operations, research and development, and commercialization efforts, which may not be available on favorable terms or at all, leading to potential delays or cessation of development.

Competition & Market Share: The biotechnology industry is highly competitive, and Abeona's product candidates may face competition from existing or new therapies, potentially limiting market share and pricing power.